27 research outputs found

    Unified traction and battery charging systems for electric vehicles: a sustainability perspective

    Get PDF
    This paper presents an analysis of unified traction and battery charging systems for electric vehicles (EVs), both in terms of operation modes and in terms of implementation cost, when compared to dedicated solutions that perform the same operation modes. Regarding the connection of the EV battery charging system with the power grid, four operation modes are analyzed: (1) Grid–to–Vehicle (G2V); (2) Vehicle–to–Grid (V2G); (3) Vehicle–to–Home (V2H); and (4) Vehicle–for–Grid (V4G). With an EV unified system, each of these operation modes can be used in single–phase and three–phase power grids. Furthermore, a cost estimation is performed for an EV unified system and for dedicated systems that can perform the same functionalities, in order to prove the benefits of the EV unified approach. The cost estimation comprises two power levels, namely 6 kW, single–phase, related to domestic installations, and 50 kW, three–phase, related to industrial installations. The relevance of unified traction and battery charging systems for EVs is proven for single–phase and three–phase power grids.This work has been supported by FCT – Fundação para a CiĂȘncia e Tecnologia within the Project Scope: UID/CEC/00319/2019. This work has been supported by the FCT Project DAIPESEV PTDC/EEI-EEE/30382/2017, and by the FCT Project new ERA4GRIDs PTDC/EEI-EEE/30283/2017

    Integrated system for traction and battery charging of electric vehicles with universal interface to the power grid

    Get PDF
    This paper proposes an integrated system for traction and battery charging of electric vehicles (EVs) with universal interface to the power grid. In the proposed system, the power electronics converters comprising the traction drive system are also used for the battery charging system, reducing the required hardware, meaning the integrated characteristic of the system. Besides, this interface is universal, since it can be performed with the three main types of power grids, namely: (1) Single-phase AC power grids; (2) Three-phase AC power grids; (3) DC power grids. In these three types of interfaces with the power grid, as well as in the traction drive operation mode, bidirectional operation is possible, framing the integration of this system into an EV in the context of smart grids. Moreover, the proposed system endows an EV with an on-board fast battery charger, whose operation allows either fast or slow battery charging. The main contributes of the proposed system are detailed in the paper, and simulation results are presented in order to attain the feasibility of the proposed system.This work has been supported by COMPETE: POCI-01-0145-FEDER-007043 and FCT -Fundacao para a Ciencia e Tecnologia within the Project Scope: UID/CEC/00319/2013. This work has been supported by FCT within the Project Scope DAIPESEV - Development of Advanced Integrated Power Electronic Systems for Electric Vehicles: PTDC/EEI-EEE/30382/2017. Mr. Tiago Sousa is supported by the doctoral scholarship SFRH/BD/134353/2017 granted by the Portuguese FCT agency. This work is part of the FCT project 0302836 NORTE-01-0145-FEDER-030283

    BUILDING BRIDGES FOR INNOVATION IN AGEING : SYNERGIES BETWEEN ACTION GROUPS OF THE EIP ON AHA

    Get PDF
    The Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) proposed six Action Groups. After almost three years of activity, many achievements have been obtained through commitments or collaborative work of the Action Groups. However, they have often worked in silos and, consequently, synergies between Action Groups have been proposed to strengthen the triple win of the EIP on AHA. The paper presents the methodology and current status of the Task Force on EIP on AHA synergies. Synergies are in line with the Action Groups' new Renovated Action Plan (2016-2018) to ensure that their future objectives are coherent and fully connected. The outcomes and impact of synergies are using the Monitoring and Assessment Framework for the EIP on AHA (MAFEIP). Eight proposals for synergies have been approved by the Task Force: Five cross-cutting synergies which can be used for all current and future synergies as they consider overarching domains (appropriate polypharmacy, citizen empowerment, teaching and coaching on AHA, deployment of synergies to EU regions, Responsible Research and Innovation), and three cross-cutting synergies focussing on current Action Group activities (falls, frailty, integrated care and chronic respiratory diseases).Peer reviewe

    Evaluating the Role of Hormone Therapy in Postmenopausal Women with Alzheimer’s Disease

    Full text link

    Theory of particle-photon coincidence experiments with a non-isotropic target

    No full text

    What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research

    Get PDF
    Experimental models that faithfully mimic the developmental pathology of sporadic Alzheimer's disease (sAD) in humans are important for testing the novel therapeutic approaches in sAD treatment. Widely used transgenic mice AD models have provided valuable insights into the molecular mechanisms underlying the memory decline but, due to the particular ÎČ-amyloid-related gene manipulation, they resemble the familial but not the sporadic AD form, and are, therefore, inappropriate for this purpose. In line with the recent findings of sAD being recognised as an insulin resistant brains state (IRBS), a new, non-transgenic, animal model has been proposed as a representative model of sAD, developed by intracerebroventricular application of the betacytotoxic drug streptozotocin (STZ-icv). The STZ-icv-treated animals (mostly rats and mice) develop IRBS associated with memory impairment and progressive cholinergic deficits, glucose hypometabolism, oxidative stress and neurodegeneration that share many features in common with sAD in humans. The therapeutic strategies (acetylcholinesterase inhibitors, antioxidants and many other drugs) that have been tested until now on the STZ-icv animal model have been reviewed and the comparability of the drugs' efficacy in this non-transgenic sAD model and the results from clinical trials on sAD patients, evaluated
    corecore